Stockreport

Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab [Yahoo! Finance]

Galecto, Inc.  (GLTO) 
PDF study exploring the combination of pembrolizumab (Keytruda®) and Galecto's GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma and head and neck s [Read more]